FDA study in the United States: Electronic cigarettes are less harmful than cigarettes, and the intake levels of various carcinogens can be reduced by up to 95%

A research paper published in the journal Tobacco Control points out that e-cigarettes are less harmful than cigarettes. After smokers switch to e-cigarettes, the levels of various carcinogenic biomarkers in their urine will decrease, up to 95%.

This study was released by researchers from the US FDA, which is authorized by the US Congress and is the highest law enforcement agency engaged in food and drug management in the United States. It is also one of the most authoritative public health agencies in the world.
It is understood that testing the level of biomarkers is a related indicator of the generation of metabolites in the urine of tobacco carcinogens inhaled by smokers. This is more revealing than simply detecting the carcinogen content in cigarette smoke.
The harm of tobacco stems from its three main culprits: tobacco's unique nitrosamines, carbon monoxide, and polycyclic aromatic hydrocarbons. FDA researchers are not concerned about this: "Many studies have confirmed that the levels of biomarkers for these three substances in the urine of e-cigarette users are extremely low or undetectable." e-cigarettes can reduce the main harm of cigarettes, which is already a clear conclusion.

As for other harmful substances, FDA researchers have searched and screened over 5000 related studies worldwide in the past 8 years. The results indicate that there is consistent evidence that e-cigarette users typically inhale lower levels of carcinogens than smokers. If smokers switch to electronic cigarettes, the content of harmful substances inhaled will also be greatly reduced.
In addition, after smokers switch to e-cigarettes, the levels of biomarkers for carcinogens such as acrylamide, acrylonitrile, ethylene oxide, and vinyl chloride in their urine will also decrease. More and more smokers are switching to e-cigarettes, hoping that our research findings can provide effective information for scientific research, clinical practice, and health policies, "said Marzena Hiler, a member of the FDA Tobacco Products Center and one of the main authors of the paper.